The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Daratumumab Or Darzalex Market Between 2026 And 2030?

The market for daratumumab or darzalex has experienced significant expansion in recent times. Its value is projected to climb from $5618.3 million in 2025 to $6189.36 million in 2026, demonstrating a compound annual growth rate (CAGR) of 10.2%. Historically, this growth can be attributed to factors such as its approval for multiple myeloma treatment, robust clinical results specifically targeting cd38, a lack of comparable alternatives for relapsed disease, widespread adoption within oncology centers, and improvements in patient survival rates.

The daratumumab or darzalex market is anticipated to exhibit robust expansion over the forthcoming years. It is projected to reach $9024.5 million by 2030, advancing at a compound annual growth rate (CAGR) of 9.9%. This projected growth throughout the forecast period stems from factors such as the broadening of combination regimens, an increasing prevalence of multiple myeloma, elevated investment in oncology, the development of new therapeutic indications, and enhanced patient access initiatives. Significant trends expected during this period include its increasing uptake in multiple myeloma treatment, its use in combination with other oncology drugs, its integration into earlier treatment lines, the provision of hospital-based monoclonal antibody therapy, and its expanding application in hematologic malignancies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19896&type=smp

What Primary Drivers Are Shaping The Daratumumab Or Darzalex Market?

An increasing occurrence of bone marrow cancer is anticipated to fuel the expansion of the daratumumab or darzalex market in the future. These cancers originate in the bone marrow, encompassing conditions like multiple myeloma and leukemia, leading to abnormal blood cell production that interferes with normal bodily functions. This surge in bone marrow cancer cases stems from an aging global demographic, enhanced diagnostic techniques, and various contributing elements including environmental factors, personal lifestyle choices, and inherited genetic susceptibilities. Daratumumab (Darzalex) aids in managing multiple myeloma, a specific form of bone marrow cancer, by precisely identifying and eliminating aberrant plasma cells within the bone marrow. For example, in January 2025, the American Cancer Society, a non-profit organization based in the US, projected approximately 3,770 new cases of primary bone and joint cancer for 2025 (comprising 2,150 in men and 1,620 in women), alongside an estimated 2,190 fatalities (with 1,240 in men and 950 in women). Consequently, the escalating incidence of bone marrow cancer is a key factor propelling the expansion of the daratumumab or darzalex market.

What Segment Categories Shape The Daratumumab Or Darzalex Market Segment Landscape?

The daratumumab or darzalex market covered in this report is segmented –

1) By Drug Type: 100Mg Injection, 400Mg Injection

2) By Distribution Channel: Pharmacies, Hospital, Other Distribution Channels

3) By Application: Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Diffuse Large B Cell Lymphoma, Other Applications

What Market Trends Are Affecting The Daratumumab Or Darzalex Market?

Major companies operating in the daratumumab or darzalex market are increasingly concentrating on a strategic pivot in oncology treatment approaches, favoring early intervention methods, particularly combination therapies, to heighten the effectiveness in addressing multiple myeloma and other malignant conditions. These combination therapies involve therapeutic approaches that utilize two or more distinct agents, each operating through different mechanisms of action, frequently working together to amplify efficacy, mitigate drug resistance, and elevate patient results, potentially yielding fewer adverse reactions when compared to single-agent treatments. An illustrative example occurred in July 2024 when Johnson & Johnson, a pharmaceutical firm based in the US, secured U.S. FDA authorization for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for use in conjunction with bortezomib, lenalidomide, and dexamethasone (D-VRd) as an induction and consolidation regimen for individuals newly diagnosed with multiple myeloma (NDMM) who are candidates for autologous stem cell transplant (ASCT). This recent endorsement provides a four-drug therapy choice right at the initial diagnosis, which could lead to enhanced patient prognoses.

Who Are The Companies Operating Across The Daratumumab Or Darzalex Market Value Chain?

Major companies operating in the daratumumab or darzalex market are Genmab A/S, Janssen Biotech Inc.

Get The Full Daratumumab Or Darzalex Market Report:

https://www.thebusinessresearchcompany.com/report/daratumumab-or-darzalex-global-market-report

Which Region Leads The Daratumumab Or Darzalex Market In Terms Of Market Share?

North America was the largest region in the daratumumab or darzalex market in 2025. The regions covered in the daratumumab or darzalex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Daratumumab Or Darzalex Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/daratumumab-or-darzalex-global-market-report

Browse Through More Reports Similar to the Global Daratumumab Or Darzalex Market 2026, By The Business Research Company

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Rheumatoid Arthritis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/rheumatoid-arthritis-drugs-global-market-report

Sarcoma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/sarcoma-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.